Results 291 to 300 of about 478,842 (334)

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

Environmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons, Marc A. Beal, Kerry L. Dearfield, George R. Douglas, Min Gi, B. Bhaskar Gollapudi, Robert H. Heflich, Katsuyoshi Horibata, Michelle Kenyon, Alexandra S. Long, David P. Lovell, Anthony M. Lynch, Meagan B. Myers, Stefan Pfuhler, Alisa Vespa, Andreas Zeller, George E. Johnson, Paul A. White   +17 more
wiley   +1 more source

Advanced extracellular vesicle immunotherapy

FlexMat, EarlyView.
A diagrammatic depiction of the therapeutic applicability of extracellular vesicles (EVs) in immunotherapy. This review explores the dual roles of tumor‐derived and immune cell‐derived EVs in cancer immunotherapy, discusses recent progress in EV engineering that improve their clinical utility, and evaluates their potential to augment existing ...
Jingjing Zhang, Yunfei Mu, Xianyue Ji, Xiaoting Jiang, Ruiheng Wang, Xianguang Ding, Lianhui Wang   +6 more
wiley   +1 more source

Exploring Transitions in Care Among Patients With Head and Neck Cancer: A Scoping Review

Head &Neck, EarlyView.
ABSTRACT Background Individuals living with and beyond head and neck cancer (HNC) experience many transitions in care (TiC), as their treatment and care involve a team of multidisciplinary healthcare providers across a variety of settings. TiC can be associated with medical error, patient dissatisfaction with care, and overuse of healthcare resources ...
L. Fillo, A. Hezam, J. Kersen, S. Kurbatfinski, A. Thomas, S. Ibadin, D. L. Lorenzetti, S. P. Chandarana, J. C. Dort, K. M. Sauro   +9 more
wiley   +1 more source

Genomic and Immune Correlates of EZH2 Expression and Activity in Olfactory Neuroblastoma

Head &Neck, EarlyView.
ABSTRACT Purpose Olfactory neuroblastoma (ONB) is a rare sinonasal malignancy with limited therapeutic options in the recurrent/metastatic setting; little is known regarding its responsiveness to immunotherapy. Inhibition of enhancer of zeste homolog 2 (EZH2) has been shown to improve T‐cell‐mediated killing and susceptibility to immune checkpoint ...
Elisabetta Xue, Tolulope Adeyelu, Harris Krause, Andrew Elliott, Ranee Mehra, Heloisa Soares, Emil Lou, Ari Vanderwalde, David Spetzler, Dara Bracken‐Clarke, Nyall R. London Jr., James L. Gulley, Charalampos S. Floudas   +12 more
wiley   +1 more source

C1orf50 Drives Malignant Melanoma Progression Through the Regulation of Stemness. [PDF]

Cancer Genomics Proteomics
Otani Y, Maekawa M, Tanaka A, Peña T, Chin VD, Rogachevskaya A, Toyooka S, Roehrl MH, Fujimura A.   +8 more
europepmc   +1 more source

Primary intracranial malignant melanoma in a pediatric patient: A rare case report. [PDF]

JAAD Case Rep
Huntsman A, Mims L, Gociman S, Mehrhoff CJ.   +3 more
europepmc   +1 more source

Global Burden and Trends of Cutaneous Malignant Melanoma in the Elderly Population: Analysis of Global Burden of Disease Study 2021. [PDF]

Clin Cosmet Investig Dermatol
Du Z, Li X, Tan W, Wang C, Wang G, Wei H, Pan Y, Wu S, Zhou Q, Lin H.   +9 more
europepmc   +1 more source

Lactoferrin based copper nanoparticles: a promising anti-cancer strategy against malignant melanoma. [PDF]

Sci Rep
Sharda D, Kaur A, Pattanayak A, Choudhury D.   +3 more
europepmc   +1 more source

Rare primary anorectal malignant melanoma presenting with painless hematochezia: a case report. [PDF]

Front Oncol
Zhong Y, Zou Y, Peng L, Hu X, Xu W.
europepmc   +1 more source

Research progress and molecular mechanism of oridonin in the treatment of malignant melanoma. [PDF]

Front Oncol
Deng T, Wu J, Cheng H, Lu J.
europepmc   +1 more source